SynAbs recent antibody innovations

11. February 2023

Decoding Matrix Metalloproteinases (MMP): A Journey towards effective Therapeutic interventions

Thanks to unique technologies to break immune tolerance, SYnAbs generate monoclonal antibodies to Matrix metalloproteinases (MMPs), extracellular proteinase enzymes involved in the degradation of the extracellular matrix.

25. January 2023

Claudin and Occludin : potential of tetraspan transmembrane proteins of cell-cell tight junctions as antibody therapeutic targets

SYnAbs generates R&D, surrogate and therapeutic monoclonal antibodies targeting occludin and claudin highly homologous transmembrane proteins

New primary monoclonal antibodies · 25. November 2022

SYnAbs is awarded a major Horizon European grant for the generation of therapeutic antibodies on transmembrane targets and highly conserved soluble proteins

Synabs announces a large Horizon European grant for the generation of therapeutic antibodies on transmembrane targets and highly conserved soluble proteins

Ion channel therapeutic monoclonal antibodies · 22. October 2022

Membrane Antibody Therapeutic Approach to Ion Channelopathies

SYnAbs' unique approach generating ultra-specific therapeutic monoclonals to ion channels and effectively treat channelopathies thanks to a unique antibody platform

New primary monoclonal antibodies · 03. October 2022

SYnAbs launches unique anti-glucagon monoclonals

SYnAbs monoclonals specific to glucagon without cross-reaction to GLP-1, Glicentin, Oxyntomodulin and Proglucagon, to diagnose diabetes and glucagonomas diseases

GPCR therapeutic monoclonal antibodies · 20. September 2022

SYnAbs signs a research agreement with Domain Therapeutics to discover therapeutic antibodies on GPCRs

SYnAbs and Domain Therapeutics enter into a strategic partnership for the discovery and development of therapeutic antibodies targeting complex G Protein Coupled Receptor targets for immuno-oncology indications

GPCR therapeutic monoclonal antibodies · 13. August 2022

G protein-coupled endothelin receptors and their natural and therapeutic ligands

From the discovery of an unique peptide ligand to the clinical relevance of ETA and ETB receptors and the current therapeutic pipeline of small molecules and monoclonal antibodies targeting these GPCR transmembrane proteins

Ion channel therapeutic monoclonal antibodies · 12. July 2022

Glutamate transporter : a brief history of excitatory amino acid transmembrane proteins

SYnAbs has developed R&D and therapeutic monoclonal antibodies against transporters and ion channel such as glutamate EAAT transmembrane targets thanks to peptide and syngeneic cell immunization strategies

Anti-small molecule hapten antibodies · 09. June 2022

TACA, promising oncology targets?

SYnAbs develops therapeutic IgG antibodies highly specific to carbohydrates by combining unique technologies and expertise to break immune tolerance in rat-LOU and transgenic animal species

GPCR therapeutic monoclonal antibodies · 30. April 2022

Therapeutic trends of G protein-coupled receptor drugs as Antibody Drug Conjugates candidates

SYnAbs can help you develop therapeutic antibody-drug conjugates by specifically targeting transmembrane proteins using innovative proprietary technologies.